BACKGROUND: Octogenarians and nonagenarians with stage II/III rectal adenocarcinomas are underrepresented in the randomized trials that have established the standard-of-care therapy of preoperative chemoradiation followed by definitive resection (ie, chemoradiation and then surgery [CRT1S]). The purpose of this study was to evaluate the impact of therapies on overall survival (OS) for patients with stage II/III rectal cancers and determine predictors of therapy within the National Cancer Data Base (NCDB). METHODS: In the NCDB, patients who were 80 years old or older and had clinical stage II/III rectal adenocarcinoma from 2004 to 2013 were queried. Kaplan-Meier analysis, log-rank testing, logistic regression, Cox proportional hazards regression, interaction effect testing, and propensity score-matched analysis were conducted. RESULTS: The criteria were met by 2723 patients: 14.9% received no treatment, 29.7% had surgery alone, 5.0% underwent short-course radiation and then surgery (RT1S), 45.3% underwent CRT1S, and 5.1% underwent surgery and then chemoradiation (S1CRT). African American race and residence in a less educated county were associated with not receiving treatment. Male sex, older age, worsening comorbidities, and receiving no treatment or undergoing surgery alone were associated with worse OS. There was no statistical difference in OS between RT1S, S1CRT, and CRT1S. Interaction testing found that CRT1S improved OS independently of age, comorbidity status, sex, race, and tumor stage. In the propensity scorematched analysis, CRT1S was associated with improved OS in comparison with surgery alone. CONCLUSIONS: A significant portion of octogenarians and nonagenarians with stage II/III rectal adenocarcinomas do not receive treatment. African American race and living in a less educated community are associated with not receiving therapy. This series suggests that CRT1S is a reasonable strategy for elderly patients who can tolerate therapy. Cancer 2017;123:4325-36. V C 2017 American Cancer Society.
INTRODUCTION
Colorectal cancer is the second leading cause of death in the United States, with an estimated 40,000 cases of rectal cancer diagnosed in the United States annually. 1 The standard-of-care therapy for stage II/III rectal cancers (cT3/4 and/or cN1) is neoadjuvant therapy, which in the United States is generally concurrent chemoradiation and then resection with total mesorectal excision (TME) technique (ie, chemoradiation and then surgery [CRT1S]) followed by adjuvant chemotherapy. These treatment paradigms were established via landmark randomized trials, including the National Surgical Adjuvant Breast and Bowel Project R-03 trial and the German Rectal Cancer Trial, which demonstrated improved disease and toxicity outcomes with preoperative chemoradiation. [2] [3] [4] Despite the literature justifying current treatment approaches, there is a paucity of data for their implementation in octogenarians and nonagenarians. These patients are routinely underrepresented in clinical trials and are undertreated because of concerns about medical fragility or utility for patients who may die of competing risk factors.
MATERIALS AND METHODS

Patient Selection
The NCDB is a large, prospectively acquired database capturing 70% of newly diagnosed malignancies in the United States, all from Commission on Cancer-accredited facilities. The data set includes detailed demographic, disease, and treatment characteristics in addition to survival outcomes.
The NCDB was queried for patients with rectal cancer diagnosed from 2004 to 2013. To be included, patients had to be 80 years or older at diagnosis, have an invasive adenocarcinoma histology, be clinically staged as II or III, and be without previous cancer diagnoses. Patients with metastatic disease at diagnosis or with incomplete treatment records were excluded (Supporting Fig. 1 [see online supporting information]). Patients were classified by the clinical stage (II or III) according to the American Joint Committee on Cancer system (7th edition). 7 Treatment was classified as follows: no treatment, surgery alone (definitive low anterior resection or abdominoperineal resection), short-course radiation and then surgery (RT1S; fewer than 6 fractions and more than 4 Gy per fraction required for inclusion), CRT1S, or definitive surgery and then chemoradiation (S1CRT). The following patient characteristics were examined: age, sex, race, insurance type (government insurance, private insurance, or no insurance), patient county of residence (urban, rural, or metro as defined by the US Census Bureau), distance from the patient's residence ZIP code to the treatment facility, year of diagnosis, percentage of residents without a high school degree in the patient's census tract (<14%, 14%-19.9%, 20%-28.9%, and 29% [quartiles]), median income of the patient's census tract (<$30,000, $30,000-$35,999, $36,000-$45,999, and $46,000 as determined by the American Community Survey), and comorbidities (as quantified by the Charlson-Deyo score). 8, 9 The following tumor characteristics were evaluated: size, grade (well, moderately, or poorly differentiated), lymphovascular space invasion (LVSI), and carcinoembryonic antigen (CEA) level (elevated, undetermined, or negative). The following treatment characteristics were evaluated: treatment facility type (community cancer center, comprehensive community cancer center, or academic program), treatment facility location within the United States (Northeast, South, Midwest, or West), extent of resection (R0 vs R1), node positivity at the time of surgery (pN0 or pN1), reason for no radiation (not part of the treatment plan, not given because of patient risk factors, patient refusal, or unknown reason), time from diagnosis to the definitive treatment start (0-30, 31-90, or >90 days), and number of lymph nodes removed at surgery (none, <10, 10-14, or >14). The chemotherapy type, the number of cycles, and patient adherence cannot be reported with the NCDB. The age and the tumor size were evaluated as continuous variables after testing revealed a linear effect on OS.
Statistical Methods
The statistical analysis was conducted with SAS 9.4 (SAS, Cary, North Carolina) and SAS macros. 10 Descriptive statistics for each variable were determined. Variables were compared across treatment groups with chi-square and analysis-of-variance tests where appropriate. The extent of resection, the node positivity at surgery, and the time from diagnosis to treatment start were compared across the 4 groups that received therapy only. Univariate and multivariate logistic regression models were fit to determine relevant predictors of receiving no treatment and receiving CRT1S; all sociodemographic variables were included. The primary endpoint of OS was defined as the months from diagnosis to death or last follow-up. Univariate Cox proportional hazards models were fit for each variable. Multivariate Cox proportional hazards models were fit for the entire cohort to include all relevant variables with a P value of .1 or less after backward elimination. Variables that directly correlated with no treatment (eg, lymph node removal and extent of resection) were not included in the multivariate logistic regression or Cox models. Next, the effect of the treatment type on OS stratified by different variables was estimated via the testing of the interaction effect between the treatment type and each significant variable. 11 The interaction analysis was considered exploratory and was not powered for statistical testing. Lymphovascular invasion and CEA levels were not included in the multivariate analysis because of the high number missing data. Kaplan-Meier curves were generated for OS estimates for the entire cohort stratified by treatment group, and comparisons of groups were performed with log-rank tests, with a P value < .05 considered statistically significant. Finally, propensity score matching was implemented to reduce the treatment selection bias. A logistic regression model predicting concurrent chemotherapy and radiation (CRT) versus surgery alone was performed to estimate the propensity scores of all covariates. Patients were then matched 1:1 on the basis of propensity scores with a greedy 5-1 digit match algorithm for sex, stage, age, Charlson-Deyo score, and facility location. 12 After the matching, the balance of the 2 groups was evaluated by standardized differences, with values < 0.1 considered negligible. 13 The OS effect in the matched sample was estimated with a Cox model with a robust variance estimator. 14, 15 Because of the small number of patients treated with short-course preoperative radiation and postoperative chemoradiation, those patients were excluded from the propensity score-matched analysis. For each survival model, the proportional hazards assumption was assessed, and no statistically significant deviations were observed.
RESULTS
Patient Characteristics
A total of 2723 patients met the study entry criteria (Supporting Table 1 summarizes the study population by treatment group.
Predictors of Receiving No Treatment
In total, 407 patients (14.9%) did not receive any treatment. In the univariate analysis, age per 1-year increase, female sex (vs male sex), black race (vs white race), living in a lower income (<$30,000) census tract (vs a higher income [$46,000] census tract), and living in a census tract in which 20% or more of the population lacked a high-school degree (vs <20%) were associated with receiving no treatment (all P values < .05; Table 3) .
OS
Among all patients, the estimated 3-and 5-year OS rates for patients receiving CRT1S were 69.0% (95% CI, 65.9%-71.9%) and 49.6% (95% CI, 45.7%-53.3%), respectively. The estimated 3-and 5-year OS rates for patients receiving S1CRT were 60.5% (95% CI, 50.8%-68.9%) and 47.4% (95% CI, 36.9%-57.2%), respectively. The estimated 3-and 5-year survival rates for patients receiving RT1S were 52.7% (95% CI, 42.8%-61.7%) and 36.0% (95% CI, 26.3%-45.7%), respectively. The estimated 3-and 5-year OS rates for patients undergoing definitive surgery alone were 40.3% (95% CI, 36.5%-44.1%) and 24.3% (95% CI, 20.6%-28.1%), respectively. The estimated 3-and 5-year OS rates for patients not receiving therapy were 9.1% (95% CI, 6.3%-12.6%) and 5.7% (95% CI, 3.5%-8.8%), respectively ( Fig. 1) .
In the univariate analysis, age per 1-year increase, a Charlson-Deyo score of 1 (vs 0), the presence of LVSI (vs no LVSI), elevated CEA levels (vs negative CEA findings), no treatment, surgery alone, RT1S (vs CRT1S), no lymph nodes removed (vs >14), R1 resection (vs R0 resection), and treatment at a facility located in the South (vs the West) were associated with worse OS (all P values < .05; interaction testing, the influence of the treatment received on OS was not dependent on age, race, sex, CharlsonDeyo score, or stage, and this indicated a benefit from CRT1S across these variables (Supporting Table 1 [see online supporting information]).
After propensity score matching, there were 560 patients in the surgery alone cohort and 560 patients in the CRT1S cohort. Undergoing surgery alone was associated with worse OS in comparison with CRT1S (HR, 1.94; 95% CI, 1.65-2.27) in this model. In the matched cohort, the estimated 3-and 5-year OS rates for patients undergoing surgery alone were 42.1% (95% CI, 37.6%-46.4%) and 23.5% (95% CI, 19.2%-28.1%), respectively. The estimated 3-and 5-year OS rates for patients receiving CRT1S were 66.2% (95% CI, 61.9%-70.2%) and 44.5% (95% CI, 39.4%-49.5%), respectively (Fig. 2) . The parametric P value was calculated with an analysis of variance for numerical covariates and with a chi-square test for categorical variates. For variables comparing treatment results, the reported P value is a log-rank comparison of the 4 groups that received therapy (the no-treatment group was not included). Bolding indicates statistical significance. Abbreviations: CEA, carcinoembryonic antigen; CRT, concurrent chemotherapy and radiation; N/A, not applicable; RT, radiation therapy.
Elderly
DISCUSSION
Our series is the largest in the literature examining treatment patterns and survival outcomes for octogenarians and nonagenarians with stage II/III rectal adenocarcinomas. We found that despite an older population, a deviation from guideline care was associated with worse OS. These results persisted in multivariate and exploratory interaction variable testing, and this suggests that the benefit from receiving therapy is independent of age, race, sex, and comorbidity status (as measured by the CharlsonDeyo score). In addition, we saw an OS benefit for patients treated with CRT1S versus surgery alone in the propensity score-matched analysis. Our series also confirmed known poor prognostic factors for rectal cancer, Original Article including incomplete resection, higher stage, male sex, advancing age, positive lymph nodes at the time of surgery, and worse comorbidities. 3, [16] [17] [18] Alarmingly, our study found that black race and living in a less educated census tract were associated with not receiving any therapy. Conversely, we found that male sex, treatment in the Midwest or Northeast, and a lower comorbidity status were associated with receiving CRT1S.
Patients who are 80 years old or older are not well represented in the randomized trials that have defined CRT1S as the standard of care for stage II/III rectal cancer. In the landmark German phase 3 rectal cancer trial, 823 patients with stage II/III rectal cancer were randomized to preoperative chemoradiation followed by TME and adjuvant 5-fluorouracil chemotherapy versus the same schedule of chemoradiation used postoperatively.
2,3
At 10 years, there was an improvement in local control in the preoperative arm (92.9%) versus the postoperative arm (89.9%) without an improvement in disease-free survival. These results shifted the historical paradigm of postoperative chemoradiation 19, 20 to a preoperative approach. However, the oldest person in this trial was 77 years old, and this led to concerns about its applicability to octogenarians and nonagenarians. In a similarly designed trial in the United States, 267 patients with cT3, cT4, or cN1 rectal cancers were randomized to preoperative chemoradiation versus postoperative chemoradiation. 4 Unlike the German trial, there was no observed difference in locoregional control (a 5-year rate of 10.7% in both arms), but there was a 5-year disease-free survival benefit from preoperative therapy versus postoperative therapy (64.7% vs 53.4%). In this trial, patients were stratified at the age of 60 years, but there is no information about the range of patient ages or about the percentage of patients aged 80 years or older. In the current series, we demonstrate that the receipt of CRT1S was associated with improved OS in multivariate analysis, exploratory interaction testing, and propensity score-matched analysis, and this suggests that preoperative CRT should be explored in octogenarians and nonagenarians with stage II/III rectal cancers and not be omitted simply because of the patient's age.
Because of their underrepresentation in landmark trials, there have been retrospective studies looking at the utility of treatment for elderly patients. In a study comparing RT1S and surgery alone in 642 patients who were 75 years old or older and had resectable rectal cancer in the Dutch Cancer Registry, local recurrence was less common in the radiation group versus the surgery alone group (2% vs 6%). 21 However, increased toxicity was seen in the RT1S group, and there was a significant increase in perioperative deaths for patients with severe comorbidities in the RT1S cohort. The authors concluded that omitting preoperative radiation may be suitable for elderly patients with additional risks. Conversely, in a recent study of 2300 patients with resectable rectal cancer from the Swedish Cancer Registry, in which 70.3% of the patients had undergone preoperative radiation, among patients with a higher comorbidity status (Charlson-Deyo score 1), there was an OS improvement with RT1S (HR, 0.65) versus surgery alone. 17 The study included 433 patients who were 80 years old or older, and a subset analysis showed a benefit in local control but not OS with RT1S. The authors concluded that omitting preoperative radiation for patients with comorbidities should be cautioned. In our series, RT1S was infrequently used (137 patients or 5.0% of the entire group), and in the multivariate analysis, these patients were found to trend toward lower OS in comparison with CRT1S patients (HR, 1.52; 95% CI, 0.98-1.96). An analysis of the Surveillance, Epidemiology, and End Results database of 21,390 localized rectal cancer patients with a median age of 68 years (interquartile range, 55-77 years) was undertaken to examine the impact of age on the therapy received and cancer outcomes. 22 The authors found that for every 5 years past 70 years, there was a 37% relative risk increase in cancerrelated mortality as well as a 46% relative risk decrease in undergoing appropriate cancer-directed surgery. The authors concluded that elderly patients have worse disease outcomes but are also more likely to not receive standard therapy. Taken together, these findings are congruent to our series because rising age and rising comorbidity status were associated with worse OS for all stages, but an OS benefit was still seen with the delivery of CRT1S with multiple statistical methodologies. Taken together, these findings indicate that there may be a benefit from CRT1S for this elderly cohort that is independent of age, race, sex, and comorbidities. In addition, we found that in the multivariate analysis, adjuvant chemoradiation had no OS difference (HR, 1.10; 95% CI, 0.83-1.46) in comparison with preoperative chemoradiation. This suggests that either approach can be justified, even in this elderly cohort, with the caveat that only 5.1% of our series had S1CRT. We found a significant number of patients aged 80 years or older who were receiving no therapy (14.9% in the entire cohort), and this is higher than the rate reported in the Surveillance, Epidemiology, and End Results study. Sociodemographic factors have been known to influence the outcomes of patients with rectal cancer. Previous studies have shown that African American race is associated with higher mortality in comparison with white race, 23, 24 and there is some suggestion that this is related to unequal access to screening. 25 These disparate outcomes are likely related to socioeconomic status, which may serve as a proxy for income, education, and access to care. 26 Our series confirms many of these findings with a database that captures 70% of newly diagnosed malignancies in the United States. In addition, our series is the first to recapitulate these socioeconomic status factors leading to a lack of care specifically in an elderly cohort of patients with rectal cancer. Because no patients in our series lacked insurance, as would be expected in an elderly population for which Medicare is available, these disparities in the treatment received are even more alarming.
Our series has several strengths and limitations. The strengths include our sample size; this is the largest assessment of stage II/III rectal cancer in octogenarians and nonagenarians ever reported. We are the first to summarize the practice patterns of this population in the United States as well as the socioeconomic status and demographic factors associated with receiving different therapies. A limitation of our study is the lack of uncaptured variables and outcomes in the NCDB, which in this respect is like other cancer registries and retrospective data analyses. We performed stratified analysis, multivariate analysis, interaction variable testing, and propensity score-matched analysis to attempt to account for these confounding variables, and there continued to be a persistent OS benefit from receiving CRT1S. The generated HRs comparing patients undergoing surgery alone with those receiving CRT1S were similar in the multivariate model (HR, 1.98; 95% CI, 1.73-2.27) and the propensity score-matched model (HR, 1.94; 95% CI, 1.65-2.27), and this suggests that the adjustments for confounders in the multivariate analysis may be adequate. However, despite our statistical methodology, there are likely confounders that cannot be evaluated. We cannot accurately report on the effects of the margin status, lymph node yield at surgery, and other treatment related factors on OS because these variables are direct functions of the treatment type. We cannot comment on the impact of adjuvant chemotherapy on OS because of NCDB coding limitations. In addition, we cannot comment on the tumor control rates or cancer-specific survival because this information is not reported in the NCDB, and it is possible that the OS benefit from CRT1S is due to competing risks of death because the patients who received CRT1S were more likely to be younger and have less severe medical comorbidities. Most prospective studies examining preoperative therapies for stage II/III rectal cancers in the TME surgical era have found a local control benefit from therapy but no survival differences, 2, 4, 27 and this further suggests that the OS differences seen in our series may be patient selection-driven despite our efforts to reduce bias. We also cannot comment on whether all definitive resections used the TME technique because this is not delineated in the NCDB, but our series is purposefully limited to the TME era to address this. Furthermore, we cannot comment on the effect of short-course preoperative radiation or postoperative chemoradiation in a propensity score-matched analysis (both treatment approaches were used) because there was a limited number of these patients in this series. In the multivariate model, the use of shortcourse radiation or adjuvant chemoradiation appeared to statistically not be associated with worse OS in comparison with CRT1S. Treatment toxicity is extremely relevant in any population and specifically in an elderly cohort, and we cannot comment on that in this series. CRT is associated with fibrosis, fecal incontinence, and myelosuppression. [28] [29] [30] Conflicting evidence exists regarding treatment toxicity in elderly patients, with one series showing that they tolerated and adhered to CRT1S comparably to younger patients, 31 whereas another series reported worse severe toxicity and more permanent stomas in comparison with younger patients. 32 In conclusion, in this analysis of the NCDB, we found that 14.9% of octogenarians and nonagenarians diagnosed with stage II/III rectal cancer did not receive cancer-directed curative therapy. Patients who received the standard-of-care therapy of preoperative chemoradiation followed by definitive resection had an OS benefit in comparison with those who received surgery alone or no therapy. We found that older age, African American race, and living in a less educated census tract, among other variables, were associated with not receiving therapy, despite all patients in our series having health insurance. Overall, this series suggests that adherence to the standard of care established through trials with younger patients should be a consideration in decision making about the risks and benefits of treatment for patients who are 80 years old or older with stage II/III rectal adenocarcinoma. Efforts to limit health care disparities should be further investigated.
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